絞り込み

16532

広告

A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.

著者 Dimopoulos MA , Kaufman JL , White D , Cook G , Rizzo M , Xu Y , Fahrbach K , Gaudig M , Slavcev M , Dearden L , Lam A
Clin Lymphoma Myeloma Leuk.2018 Jan 05 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (240view , 0users)

Full Text Sources

Miscellaneous

Previous network meta-analyses combined studies of immunomodulatory drug (IMiD)-containing and IMiD-free regimens, despite a lack of head-to-head randomized controlled trials to robustly link them. However, patients with relapsed or refractory multiple myeloma (RRMM) treated with IMiD-containing regimens differ from those treated with IMiD-free regimens, especially relating to treatment history, which is an important treatment-effect modifier requiring clinical consideration when evaluating the most appropriate subsequent treatment options. A need exists to separately assess the efficacy of treatment regimens for patients who are suitable candidates for IMiD-containing and IMiD-free regimens. The presented analyses will enable clinicians to assess the best regimens to use in patients suitable for IMiD-containing regimens.
PMID: 29456035 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード